Mochi Health
Mochi Health scored 38/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.
- COA on every lotCompounded-only supply; primary pharmacy partner Aequita was shut down by Washington State March 2025 for sterile-compounding violations · subsequent partner pharmacies not consistently disclosed35
- Cold-chain verified50
- Rx legality100% compounded model · directly targeted by April 30, 2026 503B-exclusion proposal AND post-Feb-2025 503A enforcement-discretion ending. Active Eli Lilly lawsuit over compounded tirzepatide marketing. Pharmacy-partner violations on record.25
- Compound identityIdentity assurance falls on partner pharmacy; Aequita shutdown precedent suggests state-level QC inconsistencies in the partner network40
- Dose accuracy55
- Endotoxin testingAequita's March 2025 shutdown specifically cited sterile-compounding violations · the relevant testing-discipline gap for compounded injectables35
- Refund posture50
- Channel clarityNo public brand-pivot announced as of May 2026 · entire business model premised on cheap compounded supply that the April 30 proposal closes30
- Support qualityLive virtual provider visits + 4.4/5 Trustpilot across 15k+ reviews are real positives at the patient-experience layer65
- Price transparencyFlat-rate pricing across all doses ($99/$199) is unusually transparent; total cost ~$178-278/mo with membership75
- Longitudinal retentionMost exposed front-end in the cohort to the April 30 proposal. Without a brand-pivot announcement, supply-channel sunset within months. Hold until either (a) brand integration announced or (b) the 503B comment period (closes June 29, 2026) produces a different outcome30
Brand pharmacy supply stable. Compounded channel sunsetting · April 30, 2026 FDA proposal to exclude tirzepatide from the 503B bulks list (comment closes June 29, final rule likely Q3 2026) closes the mass-compounded path. 503A patient-specific compounding survives only with documented medical necessity. Telehealth platforms (Hims, Ro, Mochi) pivoting toward brand prescriptions or oral alternatives.
Recovered from the 2023 shortage. Diabetes-coded insurance straightforward.
Oral semaglutide. Niche fit for needle-averse patients. Lower bioavailability than injectable.
Recovered from the 2023-24 shortage. Insurance coverage expanding under 2025-26 employer plans. Oral Wegovy 25mg launched Jan 2026 at $149/mo · adds a needle-free path. Compounded semaglutide channel similarly narrowing under post-Feb-2025 enforcement-discretion rules.
Lilly-direct LillyDirect channel (US-only) supplements pharmacy distribution. Stable. Brand-channel demand expected to lift through 2026 as compounded pathway closes under the April 30 FDA 503B-exclusion proposal · LillyDirect's at-launch pricing materially undercuts compounded for patients without insurance coverage.
The 11-signal rubric is public.
Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.
If Mochi Health wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.
Want a match for your situation?
Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.